Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Recruiting

Phase 2

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host DiseaseBelumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Sponsor:

Fred Hutchinson Cancer Center

Code:

NCT05996627

Conditions

Chronic Graft Versus Host Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Belumosudil

Biospecimen Collection

Electronic Health Record Review

Placebo Administration

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-24. This information was provided to ClinicalTrials.gov by Fred Hutchinson Cancer Center on 2024-11-21.